Internal Medicine, Gastroenterology · Traverse City, MI
NPI
1023184819
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
4100 Park Forest Dr, Suite 208
Traverse City, MI, 49684
Phone (231) 935-5710
Groups this clinician bills Medicare through
Medicare paid, 2024
$96K
978 services
Medicare patients, 2024
503
Average age 73
Drug cost, 2024
$804K
1,633 prescriptions
Company payments, 2025
$144
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark V Galan was code 45385 (colonoscopy - lesion removal), 164 times for 164 patients. In total Mark V Galan billed 978 services in 49 codes, and Medicare paid $96K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 45385 Colonoscopy - Lesion Removal | Facility | 164 | 164 | $199.97 | $33K |
| G0500 Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 139 | 138 | $4.69 | $652 |
| 43239 Upper GI Endoscopy | Facility | 120 | 120 | $68.70 | $8,244 |
| 45380 Lower GI Endoscopy - Other | Facility | 92 | 92 | $70.22 | $6,460 |
| 99214 Office E&M - Established | Office | 72 | 63 | $71.07 | $5,117 |
| 99232 Hospital E&M - Subsequent | Facility | 68 | 41 | $60.02 | $4,081 |
| 99223 Hospital E&M - Initial | Facility | 61 | 60 | $131.86 | $8,044 |
| 43248 Upper GI Endoscopy | Facility | 39 | 39 | $109.39 | $4,266 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 35 | 35 | $168.69 | $5,904 |
| 99204 Office E&M - New | Office | 27 | 27 | $93.34 | $2,520 |
| 99213 Office E&M - Established | Office | 24 | 23 | $50.96 | $1,223 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 15 | 15 | $168.43 | $2,526 |
| 43235 Upper GI Endoscopy | Facility | 12 | 12 | $66.31 | $796 |
By year: 2022 $120K for 1,412 services; 2023 $117K for 1,342 services; 2024 $96K for 978 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark V Galan prescribed most often to Medicare patients was Pantoprazole Sodium, with 234 prescriptions and refills. In total Mark V Galan wrote 1,633 Medicare prescriptions that cost $804K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 234 | 603 | 92 | $5,501 |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 223 | 234 | 221 | $4,077 |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 140 | 140 | 139 | $2,526 |
| Omeprazole Generic | 106 | 279 | 51 | $1,996 |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 96 | 96 | 96 | $1,576 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 84 | 84 | 84 | $5,716 |
| Mesalamine Generic | 82 | 200 | 27 | $45K |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 81 | 81 | 81 | $2,054 |
| Famotidine Generic | 60 | 128 | 20 | $500 |
| Humira(Cf) Pen Adalimumab | 48 | 48 | Under 11 | $327K |
| Xifaxan Rifaximin | 40 | 40 | Under 11 | $108K |
| Mesalamine Er Mesalamine | 39 | 63 | Under 11 | $17K |
| Creon Lipase/Protease/Amylase | 33 | 45 | 11 | $70K |
| Mercaptopurine Generic | 30 | 87 | 12 | $6,074 |
| Budesonide Dr Budesonide | 23 | 50 | 18 | $2,548 |
Brand drugs: 357 claims; generic drugs: 1,276 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark V Galan $144 ($144 in general payments such as food, travel and fees) from 2 companies. The largest payer was Medtronic, Inc. with $131.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.